|
Like and Share: Responsible Social Media Use for Today’s Oncologist |
0.50 |
06/15/2026 - 12:00am to 03/01/2027 - 11:59pm |
|
Management of High-Risk Acute Promyelocytic Leukemia in the Community Setting |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma |
1.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Maximizing Benefit, Minimizing Risk: Managing Immune Checkpoint Inhibitor Toxicities |
1.25 |
06/15/2026 - 12:00am to 03/01/2027 - 11:59pm |
|
Monitoring Toxicities in the Ambulatory Setting |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Acute Myeloid Leukemia, Version 3.2026 |
1.00 |
06/10/2026 - 12:00am to 06/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Breast Cancer, Version 5.2025 |
1.00 |
11/10/2025 - 12:00am to 11/10/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026 |
1.00 |
03/10/2026 - 12:00am to 03/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Distress Management, Version 1.2026 |
1.00 |
04/10/2026 - 12:00am to 04/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Esophageal and Esophagogastric Junction Cancers, Version 4.2026 |
1.00 |
09/16/2026 - 12:00am to 09/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026 |
1.00 |
02/10/2026 - 12:00am to 02/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Hepatocellular Carcinoma, Version 2.2026 |
1.00 |
10/13/2026 - 12:00am to 10/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Merkel Cell Carcinoma, Version 1.2024 (JA copy) |
1.00 |
04/01/2026 - 12:00am to 12/31/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Myeloproliferative Neoplasms, Version 2.2026 |
1.00 |
07/10/2026 - 12:00am to 07/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Prostate Cancer, Version 5.2026 |
1.00 |
05/10/2026 - 12:00am to 05/10/2027 - 11:59pm |
Facebook
X
LinkedIn
Forward